CARGO Therapeutics, Inc. (CRGX)
| Market Cap | 768.08M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -98.15M |
| Shares Out | 39.37M |
| EPS (ttm) | -16.53 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 86,620 |
| Open | 19.25 |
| Previous Close | 19.09 |
| Day's Range | 18.85 - 19.84 |
| 52-Week Range | 13.14 - 33.92 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 29.67 (+52.08%) |
| Earnings Date | May 24, 2024 |
About CRGX
CARGO Therapeutics, Inc., a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies. It also develops CRG-023, a tri-specific CAR T product candidate that targets tumor cells with three B-cell antigen targets. The company was formerly known as Syncopation Life Sciences, In... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for CRGX stock is "Strong Buy." The 12-month stock price forecast is $29.67, which is an increase of 52.08% from the latest price.
News
CARGO Therapeutics Names Kapil Dhingra, M.B.B.S., to Board of Directors
– Appointment adds oncology and cell therapy clinical development expertise to Board as Company continues late-stage development of its lead CAR T-cell therapy candidate, firi-cel (CRG-022) – – Appoin...
CARGO Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
– Potentially pivotal Phase 2 clinical study FIRCE-1 of firicabtagene autoleucel (CRG-022) is rapidly recruiting with 20 sites open to date; interim results expected 1H 2025 – SAN MATEO, Calif., March...
CARGO Therapeutics to Participate in the 44th Annual Cowen Healthcare Conference
CARGO Therapeutics announced that the company will participate in the 44th Annual Cowen Healthcare Conference, taking place March 4-6, 2024, in Boston, MA.
CARGO Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference
SAN MATEO, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (NASDAQ: CRGX), a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell th...
CARGO Therapeutics Reports Business Updates and Third Quarter 2023 Results
SAN MATEO, Calif., Dec. 13, 2023 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (Nasdaq: CRGX), a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell th...
Cargo Therapeutics IPO prices at $15 a share, low end of proposed range
Cargo Therapeutics CRGX, , a clinical-stage biotech specializing in cancer treatments, said late Thursday its initial public offering priced at $15 a share, the low end of its range. The company sold ...
Cargo Therapeutics to offer 18.8 million shares in IPO priced at $15 to $17 each
Cargo Therapeutics CRGX, , a clinical-stage biotech specializing in cancer treatments, set terms for its initial public offering early Monday with plans to offer 18.8 million shares priced at $15 to $...